Dr. Kurtis Anderson provides intellectual property counseling for biotechnology and pharmaceutical products, including biologics, cell therapies, gene editing, clinical antibodies, and the use of AI/ML in life sciences.

Kurtis advises startups and pharmaceutical companies on U.S. and global patent prosecution strategies, including provisional application drafting and the life cycle management of patent portfolios. He also provides landscape and freedom-to-operate analyses for investment, licensing, and acquisition deals in venture capital and private equity.

Kurtis' doctoral studies focused on structural biology, antiviral therapeutic design, and molecular biophysics. His research was funded by a Keck Fellowship in Computational and Structural Biology in Biodefense. Kurtis also synthesized thioated and chemically modified oligonucleotide aptamers for diagnostic and therapeutic uses, and his scientific work was published in peer-reviewed journals such as the Journal of the American Chemistry Society. Prior to joining Polsinelli, Kurtis was a scientific advisor and patent agent for over seven years at law firms in New York City, which included a formal in-house secondment at a gene editing therapeutic company.